Supplementary Figure 6 from Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

PDF file - 350KB, Model simulations of tumor size dynamics for 17 days of growth followed by a 21-day daily dosing regimen of 25, 50 and 100 mg/kg of LY2835219 for the full model (green line) or for the model incorporating tumor growth inhibition by cell cycle arrest alone (blue line), compared to control tumor growth (red line).